巴西统一卫生系统使用A型肉毒杆菌毒素治疗肌张力障碍的配药情况简述：巴西卫生部信息技术司数据

Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.

作者信息

Chien Hsin Fen, Rosso Ana Lucia Zuma de, Santos André Sobierajski Dos, Rieder Carlos Roberto de Mello, Maia Debora Palma, Silva Delson José da, Andrade Marcio da Cunha, Coletta Marcus Vinicius Della, Costa Maria do Desterro Leiros da, Allam Nasser, Prado Roberto César Pereira do, Borges Vanderci, Tumas Vitor, Horta Wagner de Goes

机构信息

University of São Paulo School of Medicine, Brazil.

Department of Movement Disorders of the Neurology, Service Prof. Sérgio Novis, HUCFF/UFRJ, Brazil.

出版信息

eNeurologicalSci. 2016 Jul 19;5:11-14. doi: 10.1016/j.ensci.2016.07.001. eCollection 2016 Dec.

DOI:10.1016/j.ensci.2016.07.001

PMID:29430552

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5803103/

Abstract

Botulinum toxin injections are the most effective approach for the treatment of focal dystonia. Despite growing demand and clinical indications over the years, there are few reports or publications of its use and benefit to patients seen at the Sistema Único de Saúde - SUS (Unified Health System). Analyzing the Datasus data (Unified Health System Information Department of Brazilian Ministry of Health), it was noticed that in Brazil the percentage of dystonic patient benefited from this procedure is still low. We therefore suggest some strategies to increase the dispensation of the toxin by the Brazilian Unified Health system for the dystonic patients.

摘要

肉毒杆菌毒素注射是治疗局灶性肌张力障碍最有效的方法。尽管多年来需求和临床适应症不断增加，但关于其在巴西统一卫生系统（SUS）中对患者的使用和益处的报告或出版物却很少。通过分析巴西卫生部统一卫生系统信息部的Datasus数据发现，在巴西，受益于该治疗方法的肌张力障碍患者比例仍然很低。因此，我们提出了一些策略，以增加巴西统一卫生系统对肌张力障碍患者肉毒杆菌毒素的配给量。